Research programme: extended release antipsychotic therapeutics - Alkermes

Drug Profile

Research programme: extended release antipsychotic therapeutics - Alkermes

Alternative Names: ALKS-7921; Olanzapine extended-release

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alkermes
  • Developer Alkermes plc
  • Class Piperazines; Quinolines
  • Mechanism of Action Dopamine receptor agonists; Dopamine receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psychotic disorders; Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Psychotic-disorders in USA (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA (Parenteral, Injection)
  • 16 Sep 2011 Elan Drug Technologies has merged with Alkermes Inc to form Alkermes plc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top